At the company’s annual meeting, Mylan (NSDQ:MYL) shareholders re-elected the drugmaker’s board despite a campaign spearheaded by major investors to do otherwise. The campaign hoped to encourage shareholders to vote down most of the board’s directors in response to Mylan’s drug pricing practices for its EpiPen device. The influential proxy advisory firm, ISS, also urged shareholders […]
Enable Injections launches multi-vial/syringe biologics delivery system
Enable Injections Inc. launched a new single, partial or multi-vial/syringe transfer system used to fill its large volume wearable injectors. The system enables patients to either use multiple vials or syringes to deliver biologics and high volume drugs subcutaneously. The hand-held transfer system can work with any pharmaceutical primary container closure, Enable Injections said, and […]
Adamis up, Mylan down on generic EpiPen approval
Shares in Adamis Pharmaceuticals (NSDQ:ADMP) soared more than 50% yesterday after it won FDA approval for its generic EpiPen emergency allergy pre-filled syringe, sending shares in competitor Mylan (NSDQ:MYL) down -3%. For years, Mylan has commanded more than 90% of the market for emergency epinephrine injectors. Adamis’ device, called Symjepi, is intended to be a cheaper […]
Firm urges shareholders to vote against Mylan board nominees
Shareholder advisory firm ISS issued a report today urging its clients to vote against 10 of Mylan‘s (NSDQ:MYL) board members and executive pay packages, including chief executive Heather Bresch and chairman Robert Coury. The recommendation comes after a group of influential investors, including the New York City and State pension funds, encouraged other shareholders to vote […]
Report: Mylan may have overcharged US by $1.3B for EpiPen
Mylan (NSDQ:MYL) shares dipped slightly in mid-afternoon trading today after Sen. Chuck Grassley’s (R-Iowa) office released a Health and Human Services estimate claiming that taxpayers overpaid by as much as $1.27 billion for Mylan’s EpiPen device from 2006 to 2016. The charges stem from Mylan’s decision to classify the emergency allergy auto-injector as a generic, instead of […]
Mylan board faces pressure from pension funds
Investors, including the New York City and State pension funds and the California State Teacher’s Retirement System, are urging shareholders to vote against Mylan (NSDQ:MYL) chairman Robert Coury and 5 other board members at the company’s upcoming annual meeting. Coury was compensated with more than $97 million last year and some investors aren’t happy about it. […]
Bayer wins FDA nod for connected MS auto-injector
Bayer (ETR:BAYN) said yesterday that the FDA approved a supplemental biologics license application for the BetaConnect Navigator and myBetaApp – software for its electronic BetaConnect auto-injector. The company’s BetaConnect auto-injector administers Betaseron for patients with relapsing-remitting multiple sclerosis. The newly-approved software allows patients to connect their device with the myBetaApp on their mobile device or computer […]
Artificial pancreas: These companies are racing to make one
Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in the newest video from editors at Drug Delivery Business’s sister publication Medical Design & Outsourcing. (And for a deeper dive, check out […]
Impax shares climb despite Q1 miss
Shares in Impax Laboratories (NSDQ:IPXL) rose earlier this week even though the pharmaceutical company missed expectations on Wall Street with its Q1 results. The Hayward, Calif.-based company posted profits of $7.7 million on sales of $184.4 million for the 3 months ended March 31, for bottom-line loss of -75% on sales loss of -18.2% compared with the same […]
Mylan beats Q1 earnings by a penny, misses on revenue
Shares in Mylan (NSDQ:MYL) rose 2% in pre-market activity today after the EpiPen maker beat earnings expectations on Wall Street with its 1st quarter results. The Canonsburg, Penn.-based company posted profits of $66.4 million, or 12¢ per share, on sales of $2.72 billion for the 3 months ended March 31, for bottom-line growth of 377.7% on sales growth […]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn